78471-44-0

Basic information

• Product Name: 1-(4-CHLOROBENZYL)PIPERIDIN-4-AMINE TRIFLUOROACETATE
• Synonyms: 1-(4-Chlorobenzyl)-4-aminopiperidine;1-(4-Chlorobenzyl)-4-piperidinamine;1-(4-Chlorobenzyl)piperidin-4-ylamine
• CAS NO: 78471-44-0
• Molecular Formula: C₁₂H₁₇ClN₂
• Molecular Weight: 224.7298
• Mol File: 78471-44-0.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 311.6 °C at 760 mmHg
• Flash Point: 142.2 °C
• Appearance: /
• Density: 1.15 g/cm³
• Vapor Pressure: 0.000559mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: 1-(4-CHLOROBENZYL)PIPERIDIN-4-AMINE TRIFLUOROACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-CHLOROBENZYL)PIPERIDIN-4-AMINE TRIFLUOROACETATE(78471-44-0)
• EPA Substance Registry System: 1-(4-CHLOROBENZYL)PIPERIDIN-4-AMINE TRIFLUOROACETATE(78471-44-0)

Safety Data

• Hazardous Substances Data: 78471-44-0(Hazardous Substances Data)

Usage

Chemical structure

The compound consists of a piperidine ring with an amine group and a 4-chlorobenzyl group attached to it.

Counter-ion

The trifluoroacetate ion is the counter-ion, which is often used to increase the solubility and stability of the compound.

Pharmaceutical research

It is commonly used as a building block for the synthesis of various drugs and bioactive compounds.

Therapeutic potential

The compound has been studied for its potential as a therapeutic agent in the treatment of neurological disorders and as an analgesic.

Salt form preference

The trifluoroacetate salt form of the compound is often preferred due to its enhanced properties for drug development and formulation.

Solubility

The trifluoroacetate salt form improves the solubility of the compound, which is important for drug development and formulation.

Stability

The trifluoroacetate salt form also enhances the stability of the compound, making it more suitable for pharmaceutical applications.

Molecular weight

The molecular weight of the compound without the trifluoroacetate counter-ion is approximately 213.7 g/mol.

Appearance

The compound is typically a solid, with the appearance of a white or off-white powder or crystalline solid.

InChI:InChI=1/C12H17ClN2/c13-11-3-1-10(2-4-11)9-15-7-5-12(14)6-8-15/h1-4,12H,5-9,14H2

Upstream product

• 68726-76-1 1-(p-chlorobenzyl)-4-piperidone oxime 
• 241495-43-2 4-carboxamide-1-(4-chlorobenzyl)piperidine 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 1052528-90-1 4-amino-1-(4-chloro-benzyl)-pyridinium chloride 
• 1286275-72-6 tert-butyl 1-(4-chlorobenzyl)piperidin-4-ylcarbamate 
• 873-76-7 para-Chlorobenzyl alcohol 
• 104-88-1 4-chlorobenzaldehyde 
• 73889-19-7 tert-butyl (1-benzylpiperidin-4-yl)carbamate 
• 50541-93-0 4-amino-1-benzylpiperidine 

Downstream Products

• 76167-70-9 [1-(4-Chloro-benzyl)-piperidin-4-yl]-pyrimidin-2-yl-amine 
• 130880-11-4 3,5-Dichloro-N-[1-(4-chloro-benzyl)-piperidin-4-yl]-2,6-dimethoxy-benzamide 
• 380426-03-9 2-chloro-6-[4-(1-(4-chlorobenzyl))piperidinylamino]-9-cyclopentylpurine 
• 868056-78-4 N-(2-{-3-[1-(4-chloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-2-methyl-propoxy}-4-hydroxy-phenyl)-acetamide 
• 1151759-28-2 N-{5-chloro-2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-methoxyphenyl}propaneamide 
• 936328-02-8 3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}propan-1-ol 
• 936329-38-3 2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxypropyl)oxy]benzonitrile 
• 936327-88-7 methyl 3-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxypropyl)oxy]-4-fluorophenyl}propanoate 
• 936327-96-7 methyl 3-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-fluorophenyl}propanoate 
• 936328-05-1 methyl 3-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]phenyl}propanoate 
• 936328-14-2 methyl 3-{5-chloro-2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]phenyl}propanoate 
• 936328-21-1 methyl (2E)-3-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-5-fluorophenyl}acrylate 
• 548797-97-3 N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide 
• 1033951-50-6 4-{5-bromo-2-[1-(4-chloro-benzyl)-piperidin-4-ylamino]-pyrimidin-4-yloxy}-3,5-dimethyl-benzonitrile 

Relevant articles and documents

Design and development of novel thiazole-sulfonamide derivatives as a protective agent against diabetic cataract in Wistar rats via inhibition of aldose reductase

In recent years, ALR2 (aldose reductase) inhibitors have attracted attention for their effective ability to reduce the progression of diabetes-associated cataracts. Therefore, in the present article, we intended to develop novel thiazole-sulfonamide hybrids as a potent inhibitor of ALR2. These molecules significantly inhibited the ALR2 level in the rat lenses homogenate, where the most potent compound 7b showed activity comparable to sorbinil as standard. In Wistar rats, compound 7b improved the insulin level and body weight of the experimental animal together with a reduction in the glucose output. Compound 7b showed a significant reduction in the expression of ALR2 in rat lenses in western blot analysis.

Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation

We previously discovered and validated a class of piperidinyl ureas that regulate defective in cullin neddylation 1 (DCN1)-dependent neddylation of cullins. Here, we report preliminary structure-activity relationship studies aimed at advancing our high-throughput screen hit into a tractable tool compound for dissecting the effects of acute DCN1-UBE2M inhibition on the NEDD8/cullin pathway. Structure-enabled optimization led to a 100-fold increase in biochemical potency and modestly increased solubility and permeability as compared to our initial hit. The optimized compounds inhibit the DCN1-UBE2M protein-protein interaction in our TR-FRET binding assay and inhibit cullin neddylation in our pulse-chase NEDD8 transfer assay. The optimized compounds bind to DCN1 and selectively reduce steady-state levels of neddylated CUL1 and CUL3 in a squamous cell carcinoma cell line. Ultimately, we anticipate that these studies will identify early lead compounds for clinical development for the treatment of lung squamous cell carcinomas and other cancers.

2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

A compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.